Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
3.41/6.72
|
|
Enterprise Value
6.08B
|
| Balance Sheet |
|
Book Value Per Share
16.74
|
| Cash Flow |
|
Cash Flow Yield
0.07
|
| Income Statement |
|
Total Revenue
1.54B
|
|
Operating Revenue Per Share
18.52
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, PrecisionDiagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements inEurope, Canada, Australia, Asia-Pacific, Central America and South America. |

83.82 
